These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24468919)

  • 21. Multicenter Evaluation of Survival and Toxicities of Hepatocellular Carcinoma following Radioembolization: Analysis of the RESiN Registry.
    Frantz S; Matsuoka L; Vaheesan K; Petroziello M; Golzarian J; Wang E; Gandhi R; Collins Z; Brower J; Rachakonda VM; Du L; Kennedy AS; Sze DY; Lee J; Brown DB
    J Vasc Interv Radiol; 2021 Jun; 32(6):845-852. PubMed ID: 33812981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma.
    Sundram F; Chau TC; Onkhuudai P; Bernal P; Padhy AK
    Eur J Nucl Med Mol Imaging; 2004 Feb; 31(2):250-7. PubMed ID: 15129708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma.
    Kim DY; Ryu HJ; Choi JY; Park JY; Lee DY; Kim BK; Kim SU; Ahn SH; Chon CY; Han KH
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1343-50. PubMed ID: 22486716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study.
    Cabibbo G; Maida M; Genco C; Parisi P; Peralta M; Antonucci M; Brancatelli G; Cammà C; Craxì A; Di Marco V
    World J Hepatol; 2012 Sep; 4(9):256-61. PubMed ID: 23060970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
    Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
    Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toxicity and Survival of Hepatocellular Carcinoma Patients with Hepatitis B Infection Treated with Yttrium-90 Radioembolization: An Updated 15-Year Study.
    Gao R; Gabr A; Mouli S; Riaz A; Kulik L; Lewandowski RJ; Salem R
    J Vasc Interv Radiol; 2020 Mar; 31(3):401-408.e1. PubMed ID: 31983593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radioembolization for Intermediate-Stage Hepatocellular Carcinoma Maintains Liver Function and Permits Systemic Therapy at Progression.
    Ranganathan S; Gabr A; Entezari P; Gordon AC; Riaz A; Desai K; Thornburg B; Kulik L; Kalyan A; Salem R; Lewandowski RJ
    J Vasc Interv Radiol; 2023 Jun; 34(6):968-975. PubMed ID: 36791957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
    Cosgrove DP; Reyes DK; Pawlik TM; Feng AL; Kamel IR; Geschwind JF
    Radiology; 2015 Nov; 277(2):594-603. PubMed ID: 26069923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C-arm Lipiodol CT in transcatheter arterial chemoembolization for small hepatocellular carcinoma.
    Li JJ; Zheng JS; Cui SC; Cui XW; Hu CX; Fang D; Ye LC
    World J Gastroenterol; 2015 Mar; 21(10):3035-40. PubMed ID: 25780303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival.
    Chung GE; Lee JH; Kim HY; Hwang SY; Kim JS; Chung JW; Yoon JH; Lee HS; Kim YJ
    Radiology; 2011 Feb; 258(2):627-34. PubMed ID: 21273524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A comparison of patients with hepatocellular carcinoma between a short-term (less than 6 months) survival group and a long-term (over 24 months) survival group after treatment with transcatheter arterial chemoembolization].
    Kang IK; Kim SW; Hahn SH; Cho SC; Gham CW; Lee DH
    Taehan Kan Hakhoe Chi; 2002 Jun; 8(2):189-200. PubMed ID: 12499805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 18F-FDG-PET and histopathology in 131I-lipiodol treatment for primary liver cancer.
    Risse JH; Pauleit D; Bender H; Rabe C; Fischer HP; Biersack HJ; Bucerius J
    Cancer Biother Radiopharm; 2009 Aug; 24(4):445-52. PubMed ID: 19694579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
    Wörns MA; Koch S; Niederle IM; Marquardt JU; Nguyen-Tat M; Gamstätter T; Schuchmann M; Schulze-Bergkamen H; Galle PR; Weinmann A
    Dig Liver Dis; 2013 May; 45(5):408-13. PubMed ID: 23182599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant Intraarterial Lipiodol or ¹³¹I-Lipiodol After Curative Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial.
    Dumortier J; Decullier E; Hilleret MN; Bin-Dorel S; Valette PJ; Boillot O; Partensky C; Letoublon C; Ducerf C; Leroy V; Vuillez JP; Borson-Chazot F
    J Nucl Med; 2014 Jun; 55(6):877-83. PubMed ID: 24722530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Yttrium-90 Glass-Based Microsphere Radioembolization in the Treatment of Hepatocellular Carcinoma Secondary to the Hepatitis B Virus: Safety, Efficacy, and Survival.
    Biederman DM; Titano JJ; Lee KM; Pierobon ES; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Tabori NE; Nowakowski FS; Kim E
    J Vasc Interv Radiol; 2015 Nov; 26(11):1630-8. PubMed ID: 26321014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET.
    Sabet A; Ahmadzadehfar H; Bruhman J; Sabet A; Meyer C; Wasmuth JC; Pieper CC; Biersack HJ; Ezziddin S
    Nuklearmedizin; 2014; 53(2):39-45. PubMed ID: 24777354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer.
    Marelli L; Shusang V; Buscombe JR; Cholongitas E; Stigliano R; Davies N; Tibballs J; Patch D; Meyer T; Burroughs AK
    J Nucl Med; 2009 Jun; 50(6):871-7. PubMed ID: 19443599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival outcomes in patients with advanced hepatocellular carcinoma treated with drug-eluting bead chemoembolization.
    Ray CE; Brown AC; Green TJ; Winston H; Curran C; Kreidler SM; Glueck DH; Rochon PJ
    AJR Am J Roentgenol; 2015 Feb; 204(2):440-7. PubMed ID: 25615768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longterm follow-up after transarterial chemotherapy for hepatocellular carcinoma in a Scandinavian centre.
    Norén A; Urdzik J; Duraj F; Barbier CE; Karlson BM; Haglund U
    HPB (Oxford); 2010 Nov; 12(9):637-43. PubMed ID: 20961372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.